{"id":68544,"date":"2016-06-28T18:15:01","date_gmt":"2016-06-28T18:15:01","guid":{"rendered":"https:\/\/www.pm360online.com\/?p=68544"},"modified":"2017-07-26T05:07:13","modified_gmt":"2017-07-26T05:07:13","slug":"university-of-pennsylvania-cofounds-bluepen-biomarkers-for-improved-biomarker-discovery","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/university-of-pennsylvania-cofounds-bluepen-biomarkers-for-improved-biomarker-discovery\/","title":{"rendered":"University of Pennsylvania Cofounds BluePen Biomarkers for Improved Biomarker Discovery"},"content":{"rendered":"<p>The University of Pennsylvania is helping to advance personalized medicine through improved biomarker discovery. In collaboration with Blueprint Bio, Inc. and Emerald Logic, Inc., the University has co-founded and structured <a href=\"http:\/\/bluepenbio.com\/\">BluePen Biomarkers<\/a> to conduct biomarker research and identification. Ultimately, the new company is focused on developing a comprehensive biomarker measurement and discovery pipeline for the acceleration of personalized medicine.<\/p>\n<p>The two other parties in this collaboration, Emerald Logic and Blueprint Bio, were founded with the goal of making personalized medicine a reality. Emerald Logic is helping to achieve this through their integrated \u2018omics precision analytics platform that is capable of modeling the underlying biology of disease regardless of the number or complexity of available biomarkers, lab assessments, clinical history, and demographics. Meanwhile, Blueprint Bio is working to create a validated marketplace for biomarkers signatures in personalized medicine.<\/p>\n<p>\u201cThis is innovation at its core\u2014a results-focused collaboration of academics, private industry, and research partners around the world dedicated to improving upon existing knowledge of biomarkers through a \u2018big science\u2019 approach,\u201d Michael Poisel, the Penn Center for Innovation\u2019s Director of PCI Ventures, said in a statement.<\/p>\n<p>BluePen will work with Ian Blair, PhD, the A.N. Richards Professor of Systems Pharmacology and Translational Therapeutics and Director of Center for Cancer Pharmacology in the Perelman School of Medicine at the University of Pennsylvania, to measure and integrate genomic, proteomic, metabolomic, and lipidomic biomarkers, alongside clinical data, demographics, and other phenotypic data, to provide customers and other collaborators with access to a comprehensive \u201cmulti-omics\u201d discovery platform. Through this joint venture, the University\u2019s goal is to radically improve and accelerate the discovery of relevant biomarkers, without bias toward single genes, single modalities, or inappropriate mathematical assumptions.<\/p>\n<p>\u201cOur fundamental conviction is that any intervention that has a predictable biologic outcome will have a detectable biomarker signature,\u201d Blair said in a statement. \u201cThe challenge is to detect the signature. BluePen\u2019s comprehensive multi-omics platform, married to Emerald Logic\u2019s bio-inspired signal processing analytic approach, provides a powerful solution.\u201d<\/p>\n<p>BluePen will be led by CEO Matthew Nunez who has focused on the creation of a network of collaborative clinical and research institutions that can contribute biofluid samples and patient data\u2014further augmenting the value of the platform.<\/p>\n<p>\u201cOur goal at BluePen is to help bridge biologic discoveries to clinical purpose,\u201d Nunez said in a statement. \u201cWe have been working with researchers in oncology, inflammatory diseases, neurological disorders, and a variety of other areas of interest, to identify and validate discoveries that can mitigate human suffering while decreasing treatment costs.\u201d<\/p>\n<p>Dawn Bonnell, PhD, Vice Provost for Research at the University of Pennsylvania, adds: \u201cThe BluePen Biomarkers partnerships illustrate how creative collaboration enables discoveries in academic research to translate into medical advances.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p class=\"small\">The University of Pennsylvania is helping to advance personalized medicine through improved biomarker discovery. In collaboration with Blueprint Bio, Inc. &#8230;<\/p>\n","protected":false},"author":22,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45,11991,335],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/68544"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=68544"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/68544\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=68544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=68544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=68544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}